Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages Stemming false Single Family Member true Include NPL false

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:A61K39/215

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2021/076010PHARMACEUTICAL AGENT FOR INDUCING SPECIFIC IMMUNITY AGAINST SARS-COV-2
WO 22.04.2021
Int.Class A61K 39/215
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
215Coronaviridae, e.g. avian infectious bronchitis virus
Appl.No PCT/RU2020/000591 Applicant FEDERAL STATE BUDGETARY INSTITUTION "NATIONAL RESEARCH CENTRE FOR EPIDEMIOLOGY AND MICROBIOLOGY NAMED AFTER THE HONORARY ACADEMICIAN N.F. GAMALEYA" OF THE MINISTRY OF HEALTH OF THE RUSSIAN FEDERATION Inventor ZUBKOVA, Olga Vadimovna
The invention relates to biotechnology. The claimed agent can be used for the prevention of SARS- CoV-2. There is created a pharmaceutical agent, which contains component (1), comprising an agent in the form a genome of recombinant human adenovirus serotype (26), wherein with a placed expression cassette selected from SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, and which also contains component (2), comprising an agent in the form a genome of recombinant human adenovirus serotype (5), wherein with a placed expression cassette selected from SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3. Further, there is created a pharmaceutical agent, which contains component 1, comprising an agent in the form a genome of recombinant human adenovirus serotype (26), wherein with a placed expression cassette selected from SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, and which also contains component (2), comprising an agent in the form a genome of recombinant simian adenovirus serotype (25), wherein with a placed expression cassette selected from SEQ ID NO: 4, SEQ ID NO: 2, SEQ ID NO: 3. Furthermore, there is created a pharmaceutical agent, which contains component 1, comprising an agent in the form a genome of recombinant simian adenovirus serotype (25), wherein with a placed expression cassette selected from SEQ ID NO: 4, SEQ ID NO: 2, SEQ ID NO: 3, and which also contains component (2), comprising an agent in the form a genome of recombinant human adenovirus serotype (5), wherein with a placed expression cassette selected from SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3.
2.WO/2021/076009EXPRESSION VECTOR AGAINST SEVERE ACUTE RESPIRATORY SYNDROME VIRUS SARS-COV-2
WO 22.04.2021
Int.Class A61K 39/215
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
215Coronaviridae, e.g. avian infectious bronchitis virus
Appl.No PCT/RU2020/000589 Applicant FEDERAL STATE BUDGETARY INSTITUTION "NATIONAL RESEARCH CENTRE FOR EPIDEMIOLOGY AND MICROBIOLOGY NAMED AFTER THE HONORARY ACADEMICIAN N.F. GAMALEYA" OF THE MINISTRY OF HEALTH OF THE RUSSIAN FEDERATION Inventor ZUBKOVA, Olga Vadimovna
The invention relates to biotechnology, immunology and virology. There is created an expression vector containing the genome of recombinant human adenovirus serotype 26, wherein the E1 and E3 regions are deleted, and the ORF6-Ad26 region is replaced by ORF6-Ad5, with an integrated expression cassette selected from SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 (variant 1). Therein, the sequence SEQ ID NO: 5 was used as a parental sequence of human adenovirus serotype 26. Further, there is created an expression vector, containing the genome of recombinant simian adenovirus serotype 25, wherein the E1 and E3 regions are deleted, with an integrated expression cassette selected from SEQ ID NO: 4, SEQ ID NO: 2, SEQ ID NO: 3 (variant 2). Therein, the sequence SEQ ID NO: 6 was used as a parental sequence of simian adenovirus serotype 25. Furthermore, there is created an there is created containing the genome of recombinant human adenovirus serotype 5, wherein the E1 and E3 regions are deleted, with an integrated expression cassette selected from SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 (variant 3). Therein, the sequence SEQ ID NO: 7 was used as a parental sequence of human adenovirus serotype 5. There is also developed a method of utilization of the developed expression vector for creating an immunobiological agent for the induction of specific immunity against severe acute respiratory syndrome virus SARS-CoV-2.
3.112675298一种免疫佐剂、含有所述免疫佐剂的疫苗及制备方法和应用
CN 20.04.2021
Int.Class A61K 39/215
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
215Coronaviridae, e.g. avian infectious bronchitis virus
Appl.No 202011578279.3 Applicant 中国医学科学院医学生物学研究所 Inventor 刘野
本发明提供了一种免疫佐剂、含有所述免疫佐剂的疫苗及制备方法和应用,属于免疫佐剂技术领域;所述免疫佐剂是由多肽进行叠氮化物和炔烃环加成反应制备得到的;所述多肽的氨基酸序列如SEQ ID NO:1所示,具体为XKXXXG;所述K经叠氮修饰;所述G经炔基修饰;所述X选自R、D、V、Y、Q、T和S中的一种或几种。本发免疫佐剂与传统铝佐剂相比,有更好增强体液免疫应答效果,同时也能够增强T细胞的免疫应答。
4.112679585包含禽减蛋综合征病毒基因工程亚单位疫苗的疫苗组合物及其制备方法和应用
CN 20.04.2021
Int.Class C07K 14/075
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
01DNA viruses
075Adenoviridae
Appl.No 201910990285.0 Applicant 普莱柯生物工程股份有限公司 Inventor 田克恭
本发明提供了SEQ ID NO.2所示核苷酸序列或其简并序列所编码的禽减蛋综合征病毒tFiber蛋白片段,以及该蛋白片段制备的疫苗组合物,该片段具有良好的免疫原性,其低免疫量即能产生良好的免疫效果,保护率为100%,其免疫原性较Fiber全长蛋白更好,并能与多种抗原制备联苗,对鸡和鸭群产生完全保护。
5.112661819新型冠状病毒RBD的重组病毒样颗粒及其构建方法
CN 16.04.2021
Int.Class C07K 14/165
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
08RNA viruses
165Coronaviridae, e.g. avian infectious bronchitis virus
Appl.No 202110031257.3 Applicant 军事科学院军事医学研究院军事兽医研究所 Inventor 金宁一
本发明涉及生物医学领域,特别涉及新型冠状病毒RBD的重组病毒样颗粒及其构建方法。本发明将SARS‑CoV‑2RBD序列插入至乙肝核心抗原序列,连接至pFastBacDual载体,转化到DH10Bac感受态细胞后获得重组杆粒。将重组杆粒转染至sf9细胞后进行病毒拯救,获得重组杆状病毒。PCR及WesternBlot结果显示,重组杆状病毒构建成功并且可以表达外源蛋白RBD‑HBc。透射电镜观察结果显示,电镜下可以看到40nm左右的病毒样颗粒,表明本研究成功构建了呈现SARS‑CoV‑2RBD的病毒样颗粒,为后期疫苗的研究奠定了基础。
6.112662695一种细菌生物膜囊泡(BBV)作为疫苗载体的构建方法和应用
CN 16.04.2021
Int.Class C12N 15/70
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
70Vectors or expression systems specially adapted for E. coli
Appl.No 202011623154.8 Applicant 中国医学科学院医学生物学研究所 Inventor 黄惟巍
本发明提供了一种细菌生物膜囊泡(BBV)作为疫苗载体的构建方法和应用,首次利用超高压强来驱动工程化修饰的细菌生物膜完成高效自组装,并利用ClyA在细菌外膜上组装成孔的能力携带RBD在原核系统中构建了突刺样的细菌囊泡(RBD‑BBV),RBD‑BBV高效的暴露了正确折叠的RBD在囊泡表面并展示出突刺样的囊泡结构。RBD‑BBV可以被DC细胞高效摄取并刺激DC细胞成熟,同时细菌的生物膜介导了RBD的溶酶体逃逸。RBD‑BBV免疫小鼠后在小鼠体内诱导了SARS‑COV‑2特异性的中和抗体,及SARS‑COV‑2特异性的CD4+T和CD8+T细胞应答。RBD‑BBV也在体内增强了抗原的局部稳定性,并诱导了记忆性T细胞的产生。本发明所述RBD‑BBV疫苗形式具有很多其他疫苗形式无法实现的独特特点,将可能为SARS‑CoV‑2疫苗发展提供新的思路。
7.112661865针对新型冠状病毒的疫苗以及其应用
CN 16.04.2021
Int.Class C07K 19/00
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
19Hybrid peptides
Appl.No 202011632809.8 Applicant 厚朴生物科技(苏州)有限公司 Inventor 接振旺
本发明提供了一种针对新型冠状病毒的疫苗以及其应用。本发明首次揭示一种新的改造冠状病毒刺突糖蛋白S1亚基以提高其免疫原性的方法,包括:将冠状病毒刺突糖蛋白S1亚基与定点突变的IgG Fc连接;本发明也揭示了两者融合后获得的融合多肽以及以之与铝佐剂混合后获得的疫苗。本发明的融合多肽能够被有效地表达,表达后能够形成正确的蛋白空间结构,其与铝佐剂混合而获得的疫苗具有良好的免疫原性。
8.112646005多肽、多肽疫苗及应用
CN 13.04.2021
Int.Class C07K 14/165
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
08RNA viruses
165Coronaviridae, e.g. avian infectious bronchitis virus
Appl.No 202011625769.4 Applicant 珠海碳云智能科技有限公司 Inventor 王健
本发明提供了多肽、多肽疫苗、抗原表位的筛选方法及应用。其中,多肽为SEQ ID NO:1至SEQ ID NO:154,尤其是SEQ ID NO:1至SEQ ID NO:40所示的40条肽段。通过创新性地结合多肽芯片技术筛选获得40条与冠状病毒感染,尤其是SARS‑Cov‑2病毒感染特异性相关的多肽,这些多肽能够被用来制备多肽疫苗、核酸疫苗、蛋白重组疫苗等相关疫苗产品,从而为防控此类病毒的传染和流行提供更有力的工具。
9.112641935一种含颗粒载体的亚单位疫苗及其应用
CN 13.04.2021
Int.Class A61K 39/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
Appl.No 202011102325.2 Applicant 百葵锐(天津)生物科技有限公司 Inventor 赵兴旺
本发明公开了一种含颗粒载体的亚单位疫苗及其应用,并以新型冠状病毒COVID‑19疫苗为例,提供了一种纳米病毒样颗粒新型冠状病毒COVID‑19疫苗。本发明的方案通过不同的纳米/微米材料为载体,实现亚单元抗原在载体上的自组装,充分模拟病毒或细菌的表面结构。实现提高免疫原性,简化生产工艺,降低生产成本的优点。不同的抗原蛋白通过物理吸附(静电作用,疏水作用、氢键以及其他特定的物理作用)、化学共价偶联或特异性结合吸附到不同粒径的纳米/微球颗粒上,形成表明结构与病毒相似的类病毒颗粒或与细菌结构相似的类细菌颗粒,从而提高疫苗的免疫原性。
10.112641938一种DNA重组干细胞载体新冠疫苗
CN 13.04.2021
Int.Class A61K 39/215
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
215Coronaviridae, e.g. avian infectious bronchitis virus
Appl.No 202011375242.0 Applicant 翁炳焕 Inventor 翁炳焕
一种DNA重组干细胞载体新冠疫苗,其特征在于,从干细胞样本库或日常实验后剩余的样本中获得间充质干细胞或羊水成纤维细胞,筛选、诱导成肺干细胞,然后将新冠病毒的易感基因ACE2插入已被永生化基因SV40LT和/或hTERT转染的干细胞DNA中,制备易被新冠病毒感染的易感干细胞;进而将新冠病毒M、N、E和/或S基因的RNA干扰序列shRNA插入所述易感干细胞DNA中,制备能通过ACE2将新冠病毒吸入干细胞内并能通过shRNA靶向干扰新冠病毒在干细胞内复制的DNA重组干细胞;最后将新冠病毒抗体产生基因S1‑RBD插入所述重组干细胞DNA中,制备易将新冠病毒竞争吸入干细胞内进行RNA干扰、能在体外产业化扩增并能产生新冠病毒中和抗体的DNA重组干细胞载体新冠疫苗。